Nashville, TN, United States of America

Patrick R Gentry

This inventor holds 1 USPTO granted patent. Top assignee: Vanderbilt University. Active years: 2014.


Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Patrick R. Gentry

Introduction

Patrick R. Gentry is an accomplished inventor based in Nashville, TN. He has made significant contributions to the field of neuroscience through his innovative research and patents. His work focuses on developing compounds that can aid in treating neurological dysfunction.

Latest Patents

Patrick R. Gentry holds a patent for "MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction." This patent involves compounds that serve as allosteric potentiators and positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). The implications of this research are profound, as it opens new avenues for treating various neurological disorders.

Career Highlights

Gentry is affiliated with Vanderbilt University, where he conducts his research. His work has garnered attention for its potential impact on the treatment of neurological conditions. With a focus on innovative solutions, he continues to push the boundaries of what is possible in neuroscience.

Collaborations

Throughout his career, Patrick has collaborated with notable colleagues, including P. Jeffrey Conn and Craig William Lindsley. These partnerships have enriched his research and contributed to the advancement of knowledge in the field.

Conclusion

Patrick R. Gentry exemplifies the spirit of innovation in neuroscience. His contributions through patents and collaborations highlight the importance of research in developing new treatments for neurological dysfunction. His work continues to inspire future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…